Aller au contenu principal
xMedica

NCT07293247ClinicalTrials.gov

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining…

Phase 2164 participants recherchés125 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-12-19; recorded start 2026-10-14
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 97 other studies in this databaseCounted from the lead sponsor named in the record (Alliance for Clinical Trials in Oncology)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: other.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding0/20

    Open-label

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 33 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 164 participants (target), run at 125 sites.

How this score is built
  • Enrolment21/40

    164 participants (target)

  • Site count18/25

    33 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 69 months

  • Sponsor scale7/10

    Alliance for Clinical Trials in Oncology has led 96 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding I²-PORT radiation therapy to standard therapy may be more effective than standard therapy alone in reducing the risk of cancer returning in those who have undergone surgery for NSCLC.

PRIMARY OBJECTIVES: I. To assess whether intensity-modulated post-operative radiation therapy (I²-PORT) improves disease-free survival (DFS) of patients with R0 resected ypN2 NSCLC compared to standard of care (SOC). II. To assess whether I²-PORT does not unacceptably increase (by ≥ 6.5 percentage points) the rate of severe (grade ≥ 3 per Common Terminology Criteria for Adverse Events \[CTCAE\] version \[v\] 5) late cardiopulmonary toxicity compared to SOC. SECONDARY OBJECTIVES: I. 5-year DFS, 2- and 5-year overall survival (OS). II. Local versus (vs.) regional control, rate of distant metastases. III. Acute and late adverse events (AE) rates of specific cardiac, pulmonary, and other toxicities, per CTCAE version 5.0. IV. Rates of non-mild, moderate, or severe-very severe symptoms per Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE), particularly terms related to cardiopulmonary toxicities, e.g., pain, shortness of breath, cough, wheezing, and heart palpitations. V. Subset analyses by single vs. multi-station N2 and by adequacy of surgical nodal evaluation. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI), fludeoxyglucose-positron emission tomography (FDG-PET), and blood sample collection throughout the study. ARM II: Patients undergo I²-PORT once daily (QD) Monday through Friday over 15-25 fractions over 5-6 weeks, starting 4-12 weeks after surgery. Radiation simulation should be performed within 21 days of starting I²-PORT. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on the study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.

Affections

  • Lung Non-Small Cell Carcinoma

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

* Histopathologic diagnosis of NSCLC, may have mixed or multiple histologies but no small cell component * No known EGFR mutation or ALK rearrangement * No metastatic disease (M0) per most recent PET/CT and head CT/MRI imaging * No disease progression per CT chest (including upper abdomen as per standard practice) with intravenous (IV) contrast (unless IV contrast is contraindicated) or FDG-PET performed post-neoadjuvant therapy ≤ 90 days prior to registration, either before or after surgery * No metastatic disease (M0) per head CT/MRI imaging * Prior treatment with 2-4 cycles of neoadjuvant systemic therapy with any guideline (National Comprehensive Cancer Network \[NCCN\]) concordant regimen * Lobectomy or greater oncologic surgical resection within 8 weeks prior to registration * Complete (R0) resection showing ypN2 disease * No prior radiotherapy to the lungs or mediastinum * No treatment with a VEGF inhibitor ≤ 90 days prior to registration or plan to treat with adjuvant systemic therapy including a VEGF inhibitor * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 * Platelet count ≥ 50,000/mm\^3 * Calculated (Calc.) creatinine clearance ≥ 30 mL/min * Total bilirubin ≤ 3 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 5 x upper limit of normal (ULN) * Not pregnant, because this study involves radiation therapy, which has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done ≤ 7 days prior to registration is required * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Cardiac function: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * No idiopathic pulmonary fibrosis requiring anti-fibrotic medication: Patients with idiopathic pulmonary fibrosis or inflammatory/interstitial lung disease compromising pulmonary function or requiring ongoing treatment with nintedanib, pirfenidone, or other anti-fibrotic drug are excluded * HIV-infected patients on effective anti-retroviral therapy with an undetectable viral load within 6 months are eligible for this trial

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 2
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuNONE (0)
Recrutement164 participants recherchés

Promoteur et collaborateurs

  • Alliance for Clinical Trials in Oncology Promoteur
  • National Cancer Institute (NCI) Collaborateurs

Groupes et interventions

  • Arm I (SOC chemotherapy/immunotherapy)ACTIVE_COMPARATOR

    Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.

  • Arm II (I²-PORT, SOC chemotherapy/immunotherapy)EXPERIMENTAL

    Patients undergo I²-PORT QD Monday through Friday over 15-25 fractions over 5-6 weeks. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.

Interventions

  • Intervention Biospecimen Collection

    Undergo blood sample collection

  • Médicament Chemotherapy

    Receive standard of care chemotherapy

  • Intervention Computed Tomography

    Undergo CT

  • Autre Fludeoxyglucose F-18

    Undergo FDG PET scan

  • Autre Immunotherapy

    Receive standard of care immunotherapy

  • Radiothérapie Intensity-Modulated Radiation Therapy

    Undergo I²-PORT

  • Intervention Magnetic Resonance Imaging

    Undergo MRI

Critères de jugement

  1. Critère de jugement principal

    Disease-free survival (DFS)

    DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. The median DFS for each treatment group will be estimated, and its 80% and 90% confidence intervals will be calculated using the Kaplan-Meier estimator. Additionally, the 24-month DFS rate for each treatment arm, along with its confidence intervals, will be calculated.

    Délai Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years

  2. Critère de jugement principal

    Incidence of late grade ≥ 3 cardiopulmonary toxicities

    Will be assessed according to the Common Terminology Criteria for Adverse Events version 5.0. Will be estimated for each treatment group and the difference between the two treatment groups. The confidence intervals of the rate difference at 80% and 90% significance levels will be estimated using the Miettinen-Nurminen method.

    Délai Between 3 and 24 months after protocol therapy

  3. Critère de jugement secondaire

    5-year DFS

    DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1

    Délai Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years

  4. Critère de jugement secondaire

    2-year overall survival (OS)

    Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.

    Délai Time from the date of randomization to death from all causes, assessed up to 2 years

  5. Critère de jugement secondaire

    5-year OS

    Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.

    Délai Time from the date of randomization to death from all causes, assessed up to 5 years Symptomatic skeletal event free survival (SSE-FS)

  6. Critère de jugement secondaire

    Patient-reported symptoms

    Will be assessed using Patient Reported Outcomes - Common Terminology Criteria for Adverse Events and will be evaluated for between-arm differences in proportions of patients with a maximum post-baseline score greater than 0 using Fisher's exact or chi-square test.

    Délai up to 5 years

Dates

Dates
Date de début14 octobre 2026 (estimée)
Achèvement principal31 décembre 2032 (estimée)
Achèvement1 mars 2036 (estimée)
Première publication19 décembre 2025 (réelle)
Dernière mise à jour3 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

121 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn ArborMichiganEn recrutement
Northwest Wisconsin Cancer CenterAshlandWisconsinEn recrutement
Duluth Clinic AshlandAshlandWisconsinEn recrutement
Mount Sinai Comprehensive Cancer Center at AventuraAventuraFloridaEn recrutement
Memorial Sloan Kettering Basking RidgeBasking RidgeNew JerseyEn recrutement
MaineHealth Coastal Cancer Treatment CenterBathMaineEn recrutement
UPMC-Heritage Valley Health System BeaverBeaverPennsylvaniaEn recrutement
Sanford Joe Lueken Cancer CenterBemidjiMinnesotaEn recrutement
Sanford Bismarck Medical CenterBismarckNorth DakotaEn recrutement
Illinois CancerCare-BloomingtonBloomingtonIllinoisEn recrutement
OSF Saint Joseph Medical CenterBloomingtonIllinoisEn recrutement
Essentia Health Saint Joseph's Medical CenterBrainerdMinnesotaEn recrutement
Trinity Health IHA Medical Group Hematology Oncology - BrightonBrightonMichiganEn recrutement
Trinity Health Medical Center - BrightonBrightonMichiganEn recrutement
MaineHealth Cancer Care and IV Therapy - BrunswickBrunswickMaineEn recrutement
Trinity Health Medical Center - CantonCantonMichiganEn recrutement
Trinity Health IHA Medical Group Hematology Oncology - CantonCantonMichiganEn recrutement
Illinois CancerCare-CantonCantonIllinoisEn recrutement
Saint Francis Medical CenterCape GirardeauMissouriEn recrutement
Carlisle Regional Cancer CenterCarlislePennsylvaniaEn recrutement
Illinois CancerCare-CarthageCarthageIllinoisEn recrutement
UNC Lineberger Comprehensive Cancer CenterChapel HillNorth CarolinaEn recrutement
Medical University of South CarolinaCharlestonSouth CarolinaEn recrutement
Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelseaMichiganEn recrutement
Chelsea HospitalChelseaMichiganEn recrutement
Rush MD Anderson Cancer CenterChicagoIllinoisEn recrutement
Clackamas Radiation Oncology CenterClackamasOregonEn recrutement
Baptist Memorial Hospital and Cancer Center-ColliervilleColliervilleTennesseeEn recrutement
Ohio State University Comprehensive Cancer CenterColumbusOhioEn recrutement
Memorial Sloan Kettering CommackCommackNew YorkEn recrutement
Cancer Care Specialists of Illinois - DecaturDecaturIllinoisEn recrutement
Decatur Memorial HospitalDecaturIllinoisEn recrutement
Essentia Health - Deer River ClinicDeer RiverMinnesotaEn recrutement
Essentia Health Cancer CenterDuluthMinnesotaEn recrutement
Miller-Dwan HospitalDuluthMinnesotaEn recrutement
Essentia Health Saint Mary's Medical CenterDuluthMinnesotaEn recrutement
Duke University Medical CenterDurhamNorth CarolinaEn recrutement
Marshfield Medical Center-EC Cancer CenterEau ClaireWisconsinEn recrutement
UPMC Hillman Cancer Center ErieEriePennsylvaniaEn recrutement
Illinois CancerCare-EurekaEurekaIllinoisEn recrutement
Sanford Roger Maris Cancer CenterFargoNorth DakotaEn recrutement
Sanford Broadway Medical CenterFargoNorth DakotaEn recrutement
Parkland Health Center - FarmingtonFarmingtonMissouriSuspendu
UPMC Cancer Center at UPMC HorizonFarrellPennsylvaniaEn recrutement
Illinois CancerCare-GalesburgGalesburgIllinoisEn recrutement
UPMC Cancer Centers - Arnold Palmer PavilionGreensburgPennsylvaniaEn recrutement
UPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburgPennsylvaniaEn recrutement
Memorial Sloan Kettering WestchesterHarrisonNew YorkEn recrutement
Essentia Health-Hayward ClinicHaywardWisconsinEn recrutement
Essentia Health Hibbing ClinicHibbingMinnesotaEn recrutement

75 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 3 novembre 2026

    Site ajouté

    14 sites added (125 total)

    111125

  2. 19 octobre 2026

    Date d'achèvement reportée

    Primary completion delayed 1461 days

    2028-12-312032-12-31

  3. 2 octobre 2026

    Site ajouté

    14 sites added (111 total)

    97111

  4. 2 septembre 2026

    Site ajouté

    23 sites added (97 total)

    7497

  5. 5 août 2026

    Site ajouté

    41 sites added (74 total)

    3374